MR imaging and spectroscopy in PKU

Mental Retardation and Developmental Disabilities Research Reviews

Volumn 5, Issue 2, 1999, Pages 132-135

  Moats, Rex A ^a,c   Scadeng, Miriam ^a   Nelson Jr , Marvin D ^a,b  

^a CHILDREN S HOSPITAL LOS ANGELES   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c CALIFORNIA INSTITUTE OF TECHNOLOGY   (United States)

Author keywords

Brain; Human; Magnetic resonance imaging (MRI); Magnetic resonance spectroscopy (MRS); Neutral amino acid transporter; Phenylalanine; Phenylketonuria (PKU); White matter

Indexed keywords

CHOLINE; CREATINE; GLUCOSE; GLUTAMIC ACID; GLUTAMINE; INOSITOL; N ACETYLASPARTIC ACID; PHENYLALANINE; PHENYLALANINE 4 MONOOXYGENASE;

ARTICLE; AUTOSOMAL RECESSIVE DISORDER; BLOOD LEVEL; BRAIN LEVEL; CONTROLLED STUDY; DIET THERAPY; ENZYME DEFICIENCY; HUMAN; INTELLIGENCE QUOTIENT; MENTAL DEFICIENCY; NEUROTOXICITY; NUCLEAR MAGNETIC RESONANCE IMAGING; PHENYLKETONURIA; PRIORITY JOURNAL; SPECTROSCOPY; WHITE MATTER;

EID: 0032969038     PISSN: 10804013     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1098-2779(1999)5:2<132::AID-MRDD7>3.0.CO;2-M     Document Type: Article

References (42)

1. Avison MJ, Novotony EJ, et al. 1990. Proton NMR observation of phenylalanine and an aromatic metabolite in the rabbit brain in vivo. Pediatr Res 27(6):566-570.
2. Azen CR, Koch R, et al. 1991. Intellectual development in 12 year-old children treated for phenylketonuria. Am J Dis Child 145:35-39.
3. Battistini S, Stefano N, et al. 1991. Unexpected white matter changes in an early treated PKU case and improvement after dietary treatment. Funct Neurol 6:177-180.
4. Baumeister AA, Baumeister AA. 1998. Dietary treatment of destructive behavior associated with hyperphenylalaninemia. Clin Neuropharmacol 21(1):18-27.
5. Bick U, Fahrendorf G, et al. 1991. Disturbed myelination in patients with treated hyperphenylalaninemia: evaluation with magnetic resonance imaging. Eur J Pediatr 150:185-189.
6. Bick U, Ullrich K, et al. 1993. White matter abnormalities in patients with treated hyperphenylalaninemia: magnetic resonance relaxometry and proton spectroscopy findings. Eur J Pediatr 12(152):1012-1020.
7. Blaskovics ME, Koch R, et al. 1990. MRIs and treatment in hyperphenylalaninemic patients. p 89 (Abstract).
8. Brismar J, Aqeel A, et al. 1990. Malignant hyperphenylalaninemia: CT and MR of the brain. Am J Neuroradiol 11(1):135-138.
9. Cleary MA, Walter JH, et al. 1995. Magnetic resonance imaging in phenylketonuria: Reversal of cerebral white matter change. J Pediatr 127:251-275.
10. Cleary MA, Wraith JE, et al. 1994. Magnetic resonance imaging of the brain in phenylketonuria. Lancet 344:87-90.
11. Guldberg P, Rey F, Zschocke J, et al. 1998. A European multicenter study of phenylalanine hydroxylase deficiency: Classification of 105 mutations and a general system for genotype-based prediction of metabolic phenotype. Am J Hum Genet 63:71-79.
12. Guttler F. 1980. Hyperphenylalaninemia: Diagnosis and classification of the various types of phenylalanine hydroxylase deficiency in childhood. Acta Paediatr Scand 280:1-80.
13. Hajek M et al. 1993. Proton in vivo spectroscopy of patients with Hyperphenylalanaemia. Neuropediatrics 24(2):111-112.
14. Holtzman NA, Doorninck WV, et al. 1986. Effect of age at loss of dietary control on intellectual performance and behavior of children with phenylketonuria. N Engl J Med 314:593-608.
15. Johannik K, Francois B, et al. 1994. Localized brain proton NMR spectroscopy in young adult phenylketonuria patients. Magnetic Resonance in Medicine 31:53-57.
16. Jones SJ, Turano G, et al. 1995. Visual evoked potentials in phenylketonuria: Association with brain MRI, dietary state, and IQ. J Neurol Neurosurg Psychiatry 3(59):260-265.
17. Koch R, Wenz E. 1987. Phenylketonuria. Ann Rev Nutr 7:117-135.
18. Kornguth S, Anderson M, et al. 1994. Near-microscopic magnetic resonance imaging of the brains of phenylalanine hydroxylase-deficient mice normal littermates, and of BALB/c mice at 9.4 tesla. Neuroimage 1(3):220-229.
19. 1H magnetic-resonance spectroscopy. J Mag Res Ser B 107:242-251.
20. Leuzzi V, Fabbrizi F, et al. 1992. Neuroradiological (NMR) examination in PKU patients: Clinical and biochemical correlation. (P-11 [Abstract]).
21. Leuzzi V, Transimeni G, et al. 1995. Biochemical, clinical, and neuroradiological (MRI) correlations in late detected PKU patients. J Inherit Metab Dis 18(5):624-634.
22. Lou HC, Toft PB, et al. 1992. An occipito-temporal syndrome in adolescents with optimally controlled hyperphenylalaninemia. J Inherit Metab Dis 15(5):687-695.
23. Moller JE, Ullrich K, et al. 1995. In-vivo NMR spectroscopy in patients with phenylketonuria: Change of cerebral phenylalanine levels under dietary treatment. Neuropediatr 26:199-202.
24. Pearson KD, Gean-Marton AD, et al. 1990. Phenylketonuria: MR imaging of the brain with clinical correlation. Radiology 177:437-440.
25. Pietz J, Kreis R, et al. 1996b. Phenylketonuria: Findings at MR imaging and localized in vivo H-1MR spectroscopy of the brain in patients with early treatment. Radiology 201(2):413-420.
26. Pietz J, Meyding-Lamade UK, et al. 1996a. Magnetic resonance imaging of the brain in adolescents with PKU and in one case of 6-pyruvoyl tetrahydropteridine synthasc deficiency. Eur J Pediatr 155(Supplement 1):S69-S73.
27. Shaw DWW, Maravilla KR, et al. 1991. MR imaging of phenylketonuria. AJNR 12:403-406.
28. Shaw DWW, Weinberger E, et al. 1990. Cranial MR in phenylketonuria. J Comput Asst Tomogr 14:458-460.
29. Smith I. 1994. Treatment of phenylalanine hydroxylase deficiency. Acta Paediatr Suppl 407:60-65.
30. Smith I, Beasley MG, et al. 1990. Intelligence and quality of dietary treatment in phenylketonuria. Arch Dis Child 65:472-478.
31. Thompson AJ, Smith I, et al. 1990. Neurological deterioration in young adults with phenylketonuria. Lancet 336:602-605.
32. Thompson AJ, Smith I, et al. 1991. Magnetic-resonance imaging changes in early treated patients with phenylketonuria. (letter) Lancet 337(8751):1224.
33. Thompson AJ, Tillotson S, et al. 1993. Brain MRI changes in phenylketonuria: Associations with dietary status. Brain 116:811-821.
34. Toft PB, Lou H, et al. 1994. Brain magnetic resonance imaging in children with optimally controlled hyperphenylalaninemia. J Inher Metab Dis 17:575-583.
35. Toma P. 1991. Phenylketonuria (PKU): Brain magnetic resonance (MR) findings. Neuropediatrics 22:174 (Abstract).
36. Ullrich K, Moller H, et al. 1994b. White matter abnormalities in phenylketonuria: Results of magnetic resonance measurements. Acta Paediatr Suppl 407:78-82.
37. Ullrich K, Weglage J, et al. 1994a. Cranial MRI in PKU: Evaluation of a critical threshold for blood phenylalanine. Neuropediatrics 25(5): 278-279.
38. Villasana D, Butler I, et al. 1989. Neurological deterioration in adult phenylketonuria. J Inherit Metab Dis 12(4):451-457.
39. Walter JH, Tyfield LA, et al. 1993. Biochemical control, genetic analysis and magnetic resonance imaging in patients with phenylketonuria. Eur J Pediatr 152(10):822-827.
40. Weglage J, Bick U, et al. 1997b. Progression of cerebral white matter abnormalities in early treated patients with phenylketonuria during adolescence. Neuropediatrics 28:239-240.
41. Weglage J, Moller JE, et al. 1998. In vivo NMR spectroscopy in patients with phenylketonuria: Clinical significance of interindividual differences in brain phenylalanine concentrations. J Inher Metab Dis 21:81-82.
42. Weglage J, Ullrich K, et al. 1997a. Intellectual, neurologic, and neuropsychologic outcome in untreated subjects with nonphenylketonuria hyperphenylalaninemia. German collaborative study on phenylketonuria. Pediatr Res 42(3):378-384.